SciELO - Scientific Electronic Library Online

 
vol.29 número1Asociación entre tuberculosis infantil grave e inmunización previa con BCG en un hospital de referencia nacional, Perú 1990-2000Violencia y adicciones: problemas de salud pública índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Peruana de Medicina Experimental y Salud Publica

versão impressa ISSN 1726-4634

Resumo

ASENCIOS, Luis et al. Molecular test Genotype® MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis. Rev. perú. med. exp. salud publica [online]. 2012, vol.29, n.1, pp.92-98. ISSN 1726-4634.

The Genotype®MTBDRplus molecular test is a method that allows identification of the most frequent mutations associated with resistance to major first-line antituberculosis drugs, Isoniazid (INH) and Rifampicin (RFP). The aim of this study was to evaluate the performance of the molecular test with culture and smear- positive sputum samples. We evaluated 95 cultures and 100 sputum samples with resistance profiles previously determined by the reference method "Agar Plate Proportions" (APP). The molecular test from cultures showed a sensitivity of 100 %, 97,5 % and 96,97 % for RIF, INH and MDR respectively while from sputums the sensitivity was 95,65 %, 96,77 % and 95,24 % for RIF, INH and MDR respectively. We conclude that the molecular test Genotype®MTBDRplus is a very useful tool to detect resistance to isoniazid and rifampicin simultaneously (MDR-TB) in up to 72 hours from sputum samples or cultures

Palavras-chave : Tuberculosis, multidrug-resistant; Molecular diagnostic techniques; Mutation; Isoniazid; Rifampin; Validity of tests; Peru.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons